IGIM
ALXN

I.G. Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

I.G. Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$3.93M Hold
28,000
– – 0.02% 214
2017
Q2 		$3.41M Buy
28,000
+15,000
+115% +$1.75M 0.02% 231
2017
Q1 		$1.58M Buy
+13,000
New +$1.68M 0.01% 283
2016
Q4 		– Sell
-21,290
Closed -$2.61M – 793
2016
Q3 		$2.61M Sell
21,290
-31,166
-59% -$4.01M 0.01% 469
2016
Q2 		$6.13M Buy
52,456
+20,890
+66% +$2.96M 0.02% 348
2016
Q1 		$4.39M Sell
31,566
-184
-0.6% -$27K 0.02% 389
2015
Q4 		$6.06M Buy
31,750
+1,410
+5% +$246K 0.03% 315
2015
Q3 		$4.75M Buy
30,340
+19,165
+171% +$3.5M 0.02% 339
2015
Q2 		$2.02M Buy
11,175
+2,490
+29% +$430K 0.01% 512
2015
Q1 		$1.5M Buy
+8,685
New +$1.57M 0.01% 558
2014
Q1 		– Sell
-10,880
Closed -$1.45M – 887
2013
Q4 		$1.45M Sell
10,880
-6,860
-39% -$823K 0.01% 500
2013
Q3 		$2.06M Buy
17,740
+4,330
+32% +$475K 0.01% 452
2013
Q2 		$1.24M Buy
+13,410
New +$1.29M 0.01% 521

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

I.G. Investment Management's ALXN Position: Q3 2017 in Review

I.G. Investment Management held its Alexion Pharmaceuticals (ALXN) position steady in Q3 2017 at 28,000 shares worth $3.93M. The position accounts for 0.02% of the portfolio, ranked #214.

I.G. Investment Management first reported a position in ALXN in Q2 2013 and has held it in 13 quarters since. The position peaked at $6.13M in Q2 2016. 595 funds tracked by Wall St. Rank hold ALXN as of Q3 2017.

  • I.G. Investment Management held 28,000 shares of Alexion Pharmaceuticals worth $3.93M as of Q3 2017.
  • I.G. Investment Management left its Alexion Pharmaceuticals share count unchanged in Q3 2017.
  • Alexion Pharmaceuticals made up 0.02% of I.G. Investment Management's portfolio in Q3 2017, its #214 holding.
  • I.G. Investment Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 13 quarters since.
  • I.G. Investment Management's Alexion Pharmaceuticals position peaked at $6.13M in Q2 2016.
  • 595 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2017.

Based on I.G. Investment Management's 13F filing for Q3 2017, filed 14 Nov 2017.